Yan Yongmin, Zuo Xiangsheng, Wei Daoyan
Departments of Gastroenterology, Hepatology & Nutrition and Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; School of Medical Sciences and Laboratory Medicine, Jiangsu University, Zhenjiang, People's Republic of China.
Departments of Gastroenterology, Hepatology & Nutrition and Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; School of Medical Sciences and Laboratory Medicine, Jiangsu University, Zhenjiang, People's Republic of China
Stem Cells Transl Med. 2015 Sep;4(9):1033-43. doi: 10.5966/sctm.2015-0048. Epub 2015 Jul 1.
The reception and integration of the plethora of signals a cell receives from its microenvironment determines the cell's fate. CD44 functions as a receptor for hyaluronan and many other extracellular matrix components, as well as a cofactor for growth factors and cytokines, and thus, CD44 is a signaling platform that integrates cellular microenvironmental cues with growth factor and cytokine signals and transduces signals to membrane-associated cytoskeletal proteins or to the nucleus to regulate a variety of gene expression levels related to cell-matrix adhesion, cell migration, proliferation, differentiation, and survival. Accumulating evidence indicates that CD44, especially CD44v isoforms, are cancer stem cell (CSC) markers and critical players in regulating the properties of CSCs, including self-renewal, tumor initiation, metastasis, and chemoradioresistance. Furthermore, there is ample evidence that CD44, especially CD44v isoforms, are valuable prognostic markers in various types of tumors. Therefore, therapies that target CD44 may destroy the CSC population, and this holds great promise for the cure of life-threatening cancers. However, many challenges remain to determining how best to use CD44 as a biomarker and therapeutic target. Here we summarize the current findings concerning the critical role of CD44/CD44v in the regulation of cancer stemness and the research status of CD44/CD44v as biomarkers and therapeutic targets in cancer. We also discuss the current challenges and future directions that may lead to the best use of CD44/CD44v for clinical applications.
Mounting evidence indicates that cancer stem cells (CSCs) are mainly responsible for cancer aggressiveness, drug resistance, and tumor relapse. CD44, especially CD44v isoforms, have been identified as CSC surface markers for isolating and enriching CSCs in different types of cancers. The current findings concerning the critical role of CD44/CD44v in regulation of cancer stemness and the research status of CD44/CD44v as biomarkers and therapeutic targets in cancer are summarized. The current challenges and future directions that may lead to best use of CD44/CD44v for clinical applications are also discussed.
细胞从其微环境接收的大量信号的接收和整合决定了细胞的命运。CD44作为透明质酸和许多其他细胞外基质成分的受体,以及生长因子和细胞因子的辅助因子,因此,CD44是一个信号平台,它将细胞微环境线索与生长因子和细胞因子信号整合,并将信号转导至膜相关细胞骨架蛋白或细胞核,以调节与细胞-基质粘附、细胞迁移、增殖、分化和存活相关的各种基因表达水平。越来越多的证据表明,CD44,尤其是CD44v异构体,是癌症干细胞(CSC)标志物,并且在调节CSC的特性(包括自我更新、肿瘤起始、转移和放化疗抗性)中起着关键作用。此外,有充分的证据表明,CD44,尤其是CD44v异构体,是各种类型肿瘤中有价值的预后标志物。因此,靶向CD44的疗法可能会破坏CSC群体,这为治愈危及生命的癌症带来了巨大希望。然而,在确定如何最好地将CD44用作生物标志物和治疗靶点方面仍存在许多挑战。在这里,我们总结了关于CD44/CD44v在癌症干性调节中的关键作用的当前发现,以及CD44/CD44v作为癌症生物标志物和治疗靶点的研究现状。我们还讨论了当前的挑战和未来方向,这些可能会导致CD44/CD44v在临床应用中的最佳利用。
越来越多的证据表明,癌症干细胞(CSC)是癌症侵袭性、耐药性和肿瘤复发的主要原因。CD44,尤其是CD44v异构体已被确定为用于分离和富集不同类型癌症中CSC的CSC表面标志物。总结了关于CD44/CD44v在癌症干性调节中的关键作用的当前发现,以及CD44/CD44v作为癌症生物标志物和治疗靶点的研究现状。还讨论了当前的挑战和未来方向,这些可能会导致CD44/CD44v在临床应用中的最佳利用。